About eScience Info's Newsletter This is a free weekly eNewsletter for Life Science Scientists. eScienceInfo has established itself as the leading provider of up-to-the-minute information for Scientists. Now, we're enhancing our services to better meet the needs of our readers. For years we've searched out the latest grants available and consolidated the information into one easy-to-read e-newsletter. Then we delivered it right to your inbox very Monday to save you the hundreds of hours that it would take to search out that information yourself.
RARE DISEASE Research Grants eligibility for funding up to $1,000,000
New Award Seeks to Accelerate the Development of Novel Therapies for Rare Diseases. Harrington Discovery Institute announces the call for proposals for the 2018 Harrington Rare Disease Scholar Award. Harrington Discovery Institute announces the call for proposals for the 2018 Harrington Rare Disease Scholar Award.
The Harrington Rare Disease Scholar Award was created to advance breakthrough research into cures for rare diseases. The program is sponsored by Takeda Pharmaceutical Company and overseen by Harrington Discovery Institute.
Letters of Intent are now being accepted through midnight on July 19, 2017.
Stem Cell Metabolism: a potential target for Cancer therapy
By Jeya Chelliah B.Vsc Ph.D
Although all cells rely on metabolism for their energy supply, in stem cells, the metabolic pathways appear to play a crucial role in balancing stem cell maintenance and differentiation. A complete understanding of the underlying mechanisms will not only provide important insights into this relationship, but may also contribute to the development of novel therapeutic strategies for patients with cancer or other lifethreatening illnesses in which tissue generation is disturbed.
Most cancer cells, for example, exhibit increased glycolysis. This appears to be due to defects in mitochondria, abnormal expression of metabolic enzymes and the low oxygen tension in the tumor microenvironment. This increased dependence of cancer cells on glycolytic pathways allows the development of small molecules that preferentially kill cancer cells by pharmacological inhibition of glycolysis.